Shield has put out a business update following the recent topline failure of its Phase 3 study of Feraccru in IDA in CKD. It looks like sensible actions are being taken to (i) preserve cash runway, now 'at least' end Q4 2018 vs prior end Q2 (ii) analyse in detail the CKD data to look for confounding factors that might have impacted the study, due by end March (iii) report the H2H study results this year, thus within the cash runway (iv) explore how a US filing might still be possible as well as ....